Europe Human Microbiome

The Europe human microbiome market is expected to reach USD 1.31 billion by 2031, growing from USD 0.29 billion in 2025 at a CAGR of 28.6% from 2025 to 2031.

Ferring B.V. (Switzerland), OptiBiotix Health PLC (UK), BioGaia (Sweden), MaaT Pharma (France), Actial Farmaceutica srl (Italy), Infant Bacterial Therapeutics AB (Sweden), OxThera (Sweden), Nexbiome (France), Enterome SA (France), and SNIPR BIOME (Denmark) are some of the key players in the market. These market players have focused on product launches, acquisitions, agreements, collaborations, and expansions to improve their market position. In December 2023, Ferring signed a license agreement with PharmaBiome to develop and commercialize defined consortium microbiome therapeutics for gastroenterological disorders.

To know about the assumptions considered for the study download the pdf brochure

FERRING B.V. (SWITZERLAND):

Ferring Pharmaceuticals is working on microbiome-based therapeutics for areas such as reproductive medicine, maternal health, gastroenterology, and urology. The company acquired Rebiotix, which engaged in the development of live biotherapeutic products, to support its own growth. One of the developments is Rebyota, an FDA-approved fecal microbiota therapy to prevent recurrent Clostridioides difficile infection. The organization collaborates with leading academic institutions worldwide, such as the Karolinska Institutet, Imperial College London, and Oxford University, to study live microbial consortia, bacteriophage therapies, and microbiome diagnostics. Along with its research, development, and production units in various parts of the world, the company continues to advance its microbiome programs at the preclinical and clinical stages.

 OptiBiotix Health PLC (UK):

OptiBiotix Health PLC (UK) designs microbiome modulators that change microorganisms in the body through food ingredients, dietary supplements, and medical nutrition. The company focuses on metabolic and lifestyle-related disorders like obesity, high cholesterol, and diabetes. Through its proprietary platforms such as SweetBiotix and OptiBiotic, OptiBiotix discovers microbiome modulators that have been demonstrated to influence metabolism, appetite, lipid balance, and energy regulation. OptiBiotix sells branded white-label products in Europe and collaborates with research companies to build microbiome science and thus open up more preventive health and metabolic wellness applications.

 BioGaia (Sweden):

BioGaia AB specializes in probiotics and microbiome products using clinically validated strains. The company develops and distributes tablets, drops, and lozenges for pediatric, adult, and general wellness applications. The company markets its supplements globally in over 100 countries through direct sales and partnerships. The company’s research is supported by clinical trials involving studies on gastrointestinal health and immunity. BioGaia AB drives innovation in next-generation consumer probiotics, focusing on research-based improvements in gut microbiota resilience.

Market Ranking

The Europe human microbiome market is moderately consolidated, with most of the influence being held by Ferring B.V. (Switzerland), Health PLC (UK), and BioGaia (Sweden). Ferring is a leader in live biotherapeutics, offering products for the treatment of recurrent Clostridioides difficile infections. OptiBiotix Health Plc concentrates mainly on microbiome-modulating compounds for metabolic health and preventive wellness, utilizing proprietary technologies and research collaborations. BioGaia AB is obvious in probiotic solutions that promote immune system health, gut health, and overall well-being in the EU, as well as research-driven innovations. These three companies are the main drivers of Europe’s market growth, innovation, and scientific advancement, which is further supported by the newly emerging European firms that contribute to product variety and progress in microbiome research.

Related Reports:

Europe Muman Microbiome Market by Process (Target Selection, Hit-to-lead), Type (Chemistry, Biology), Drug Type (Small Molecule, Biologics), Therapeutic Area (Oncology, Neurology, Infectious), End User (Pharma, Biotech, Academic) - Global Forecast to 2028

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com